Stabilized poly(beta-amino acid) nanoparticles for tissue-selective gene delivery
Innovative stabilized nanoparticles enhance tissue-specific gene delivery by combining covalent and electrostatic conjugation. This approach aims to improve drug-nanoparticle stability and specificity, enabling targeted delivery of DNA-based drugs and gene editing applications.
Overview
Stabilized poly(beta-amino acid) nanoparticles present a groundbreaking approach to tissue-selective gene delivery. By integrating covalent conjugation with traditional electrostatic interactions, this technology enhances the stability and specificity of DNA-based drug delivery systems. The incorporation of a peptide library further refines the nanoparticles' ability to target specific tissues, ultimately improving therapeutic outcomes and expanding the applicability of gene therapies.
Technical specifications
Key features:
- Covalent and electrostatic conjugation: Enhances nanoparticle stability, ensuring effective drug delivery and endosomal escape.
- Peptide modification: Utilizes a library of peptides to control the protein corona, achieving tissue-specific delivery.
- Biocompatible polymeric nanoparticles: Designed for targeted delivery of various nucleic acids, enhancing therapeutic potential.
- Therapeutic testing: Includes validation using a Td tomato model for gene editing applications.
Technology readiness level
This technology is at TRL 4, indicating that it has been validated in laboratory environments and is progressing towards more extensive testing and potential clinical applications.
About University of Texas Southwestern Medical Center
UT Southwestern Medical Center is a leading academic medical center within the University of Texas System, combining biomedical research, education, and a major clinical enterprise in Dallas. Co-located hospitals and outpatient networks provide direct access to clinicians, diverse patient populations, and real‑world data, enabling rapid design and execution of clinical studies. Companies engage through on‑campus incubator space, shared core facilities, and collaboration models that range from sponsored research to multi‑site trials. Research is supported primarily by NIH, with additional competitive federal awards from other national agencies. A dedicated technology transfer office streamlines IP protection, licensing, and startup formation to accelerate commercialization.
Inquire about this partnering listing
Industry applications
delivered to your inbox.